Factors Influencing the Outcome of Head and Neck Cancer of Unknown Primary (HNCUP).
CUP syndrome
head and neck cancer
multivariate analysis
neck dissection
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 May 2022
10 May 2022
Historique:
received:
10
03
2022
revised:
03
05
2022
accepted:
06
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Background: This study on patients with head and neck cancer of unknown primary (HNCUP) assesses the impact of surgical and non-surgical treatment modalities and the tumour biology on the oncological outcome. Methods: A total of 80 patients with HNCUP (UICC I−IV) were treated with simultaneous neck dissection followed by adjuvant therapy, between 1 January 2007 and 31 March 2020. As the primary objective, the influence of treatment modalities on the overall survival (OS), the disease-specific survival (DSS) and the progression-free survival (PFS) were analysed in terms of cox regression and recursive partitioning. The tumour biology served as secondary objectives. Results: The 5-year OS for the entire cohort was 67.7%, (95% CI: 54.2−81.2%), the 5-year DSS was 82.3% (72.1−92.5%) and the 5-year PFS was 72.8% (61.8−83.8%). Cox regression revealed that patients undergoing adjuvant radiotherapy only had a four times higher risk to die compared to patients receiving chemoradiation therapy (HR = 4.45 (1.40; 14.17), p = 0.012). The development of distant metastases had a significantly negative impact on OS (HR = 8.24 (3.21−21.15), p < 0.001) and DSS (HR = 23.79 (6.32−89.56), p < 0.001). Recursive portioning underlined the negative influence of distant metastases on OS (3.2-fold increase in death probability) and DSS (4.3-fold increase in death probability), while an UICC stage of IVb increased the risk for further progression of the disease by a factor of 2. Conclusions: The presence of distant metastases as well as adjuvant treatment with radiation without concomitant chemotherapy, were among others, significant predictors for the overall survival of HNCUP patients, with distant metastases being the most significant predictor.
Identifiants
pubmed: 35628814
pii: jcm11102689
doi: 10.3390/jcm11102689
pmc: PMC9143827
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer. 1989 Jul 15;64(2):510-5
pubmed: 2736495
J Otolaryngol Head Neck Surg. 2017 Jun 10;46(1):45
pubmed: 28601094
Oral Oncol. 2012 Nov;48(11):1178-84
pubmed: 22739067
Laryngoscope. 2019 Mar;129(3):684-691
pubmed: 30151832
Ann Oncol. 2003 Aug;14(8):1306-11
pubmed: 12881397
JAMA Otolaryngol Head Neck Surg. 2016 Mar;142(3):223-8
pubmed: 26769661
Head Neck. 2007 Jun;29(6):585-90
pubmed: 17274051
Chin J Cancer. 2012 Oct;31(10):484-90
pubmed: 22692070
Ann Surg Oncol. 2011 Aug;18(8):2310-7
pubmed: 21336511
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Laryngoscope. 2021 Sep;131(9):E2534-E2542
pubmed: 33734438
Anticancer Res. 2016 Feb;36(2):487-93
pubmed: 26851001
Ann Otol Rhinol Laryngol. 2009 Sep;118(9):662-9
pubmed: 19810608
Strahlenther Onkol. 1997 Jul;173(7):362-8
pubmed: 9265258
Head Neck. 2011 Sep;33(9):1245-51
pubmed: 20967874
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Strahlenther Onkol. 2019 Dec;195(12):1041-1049
pubmed: 31586229
J Urol. 2003 Jul;170(1):35-41
pubmed: 12796639
Cancer. 2009 Dec 15;115(24):5700-10
pubmed: 19691095
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1405-11
pubmed: 21177045
J Clin Oncol. 2015 Oct 10;33(29):3328-37
pubmed: 26351351
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1051-8
pubmed: 17716824
PLoS One. 2014 Nov 04;9(11):e110456
pubmed: 25369118
Arch Otolaryngol Head Neck Surg. 1991 Jun;117(6):601-5
pubmed: 2036180
J Cancer Res Ther. 2015 Oct;11 Suppl 2:C161-7
pubmed: 26506869
Oncology. 2014;86(3):170-6
pubmed: 24732431
Head Neck. 2014 Dec;36(12):1677-84
pubmed: 24115269
Radiother Oncol. 2000 May;55(2):121-9
pubmed: 10799723
Am J Otolaryngol. 2011 Jul-Aug;32(4):286-90
pubmed: 20719404
Anticancer Res. 2014 Jan;34(1):243-8
pubmed: 24403470
Int J Cancer. 2015 Apr 1;136(7):1494-503
pubmed: 24622970
ORL J Otorhinolaryngol Relat Spec. 2014;76(3):137-46
pubmed: 24993345
Strahlenther Onkol. 2020 May;196(5):474-484
pubmed: 31832696
Int J Oncol. 2014 Jun;44(6):1799-805
pubmed: 24676623
Am J Otolaryngol. 2017 Sep - Oct;38(5):588-592
pubmed: 28633765
Head Neck. 2013 Jan;35(1):123-32
pubmed: 22034046
J Clin Oncol. 2020 Aug 1;38(22):2570-2596
pubmed: 32324430
BMC Cancer. 2021 Nov 18;21(1):1236
pubmed: 34794411
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Laryngoscope. 2012 Jun;122(6):1279-82
pubmed: 22538837
Anticancer Res. 2013 Nov;33(11):5187-92
pubmed: 24222168